≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Neuromyelitis optica

Endpoint Browser PheWeb

G6_NMO

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — G36.0
  • Hospital discharge: ICD-9 — 3410A
  • Hospital discharge: ICD-8 — 34101
  • Cause of death: ICD-10 — G36.0
  • Cause of death: ICD-9 — 3410A
  • Cause of death: ICD-8 — 34101

2 out of 7 registries used, show all original rules.

103

4. Check minimum number of events

None

103

5. Include endpoints

None

103

6. Filter based on genotype QC (FinnGen only)

100

Control definitions (FinnGen only)

Control exclude
G6_DEMYEL

Extra metadata

Level in the ICD hierarchy
4

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded (different definition than used in FinnGen).

-FinnGen-

Key figures

All Female Male
Number of individuals 100 81 19
Unadjusted period prevalence (%) 0.02 0.03 0.01
Median age at first event (years) 43.03 41.82 48.18

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
103
Matched controls
1030
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G36.0
ICD-10 Finland
Neuromyelitis optica [Devic]
+∞
133.3
97
*
G35
ICD-10 Finland
Multiple sclerosis
+∞
74.2
62
*
H46
ICD-10 Finland
Optic neuritis
395.5
69.8
63
*
109
Kela drug reimbursment
Multiple sclerosis
+∞
54.0
47
*
303
Kela drug reimbursment
Dimethyl fumarate, interferon beta, glatiramer acetate and teriflunomid (Multiple sclerosis)
+∞
50.2
44
*
XCK00
NOMESCO Finland
Perimetry
26.7
49.7
39
23
157
Kela drug reimbursment
Dimethyl fumarate, glatiramer acetate, interferon beta and teriflunomid (Multiple sclerosis)
+∞
45.2
40
*
L03AB07
ATC
interferon beta-1a; parenteral
+∞
35.5
32
*
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
12.3
35.1
47
66
L03AX13
ATC
glatiramer acetate; parenteral
+∞
33.1
30
*
G37.9
ICD-10 Finland
Demyelinating disease of central nervous system, unspecified
+∞
29.6
27
*
TAB00
NOMESCO Finland
Lumbar puncture
13.0
29.0
33
36
ZX120
NOMESCO Finland
Intravenous
11.0
27.9
37
50
N86
ICPC
Multiple sclerosis
+∞
26.2
24
*
XA800
NOMESCO Finland
Neuropsychological investigation
11.7
22.2
26
29
Z01.0
ICD-10 Finland
Examination of eyes and vision
7.0
21.3
47
110
164
Kela drug reimbursment
Fingolimod
+∞
19.4
18
*
L04AA27
ATC
[U] fingolimod
+∞
18.3
17
*
353
Kela drug reimbursment
Cladribine and fingolimod
+∞
17.1
16
*
XCW99
NOMESCO Finland
Other investigative procedure of eye
7.5
16.4
28
49
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
7.0
14.9
27
50
XCD10
NOMESCO Finland
Electrophysiological examination of eye
27.1
14.9
20
9
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
35.8
14.4
18
6
L03AB08
ATC
interferon beta-1b; parenteral
+∞
13.9
13
*
L04AA31
ATC
[U] teriflunomide
+∞
12.8
12
*
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
26.7
12.0
16
7
G04BD12
ATC
mirabegron; oral
6.3
11.9
23
45
N04BB01
ATC
amantadine; oral
73.5
11.9
13
*
2AB04, ,
NOMESCO Finland
+∞
11.7
11
*
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
6.2
11.6
23
46
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
14.3
11.4
19
16
L04AX01
ATC
azathioprine; systemic
13.4
11.1
19
17
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
5.1
10.8
27
67
Z3226
NOMESCO Finland
Physiotherapist
4.4
10.7
36
113
CS444
NOMESCO Finland
Visual field testing with Octopus automated perimetry
15.4
10.6
17
13
M03BX01
ATC
baclofen; systemic
22.8
10.1
14
7
L28
ICPC
Limited function/disability (L)
4.3
9.8
32
98
N99
ICPC
Neurological disease other
109.7
9.6
10
*
F02.89*G35
ICD-10 Finland
Dementia in multiple sclerosis
+∞
9.5
9
*
N07XX09
ATC
[U] dimethyl fumarate
+∞
9.5
9
*
R1250
NOMESCO Finland
Evaluation of functional capability
12.4
9.2
16
15
UKC02
NOMESCO Finland
Cystoscopy
4.9
9.1
23
57
XKD06
NOMESCO Finland
Physiologic investigation of micturition
16.0
9.0
14
10
H53.1
ICD-10 Finland
Subjective visual disturbances
5.3
8.8
20
45
NA2CG
NOMESCO Finland
Thoracal spine extensive MRI examination with high intensity magnet
30.4
8.7
11
*
H48.1*G35
ICD-10 Finland
Retrobulbar neuritis in multiple sclerosis
+∞
8.4
8
*
R20.2
ICD-10 Finland
Paraesthesia of skin
4.6
8.2
22
57
XKC03
NOMESCO Finland
Water cystometry
14.7
8.1
13
10
G04BD09
ATC
trospium; oral
27.4
7.7
10
*
XCK10
NOMESCO Finland
Photography of fundus of eye
5.0
7.6
18
42
G97.0
ICD-10 Finland
Cerebrospinal fluid leak from spinal puncture
17.4
7.4
11
7
G36.9
ICD-10 Finland
Acute disseminated demyelination, unspecified
+∞
7.4
7
*
WW400
NOMESCO Finland
Plasmaferesis
+∞
7.4
7
*
N06BA07
ATC
modafinil; oral
+∞
7.4
7
*
L04AE01
ATC
fingolimod; oral
+∞
7.4
7
*
N39.4
ICD-10 Finland
Other specified urinary incontinence
4.9
7.4
18
43
ZXA10
NOMESCO Finland
Bilateral
3.5
7.0
29
103
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
18.2
6.9
10
6
TAB22
NOMESCO Finland
Stoppin epidural fluid escape with coagulated blood
24.4
6.8
9
*
J01EA01
ATC
trimethoprim; systemic
3.0
6.8
43
197
A28
ICPC
Limited function/disability NOS
4.1
6.7
21
61
Z3231
NOMESCO Finland
Registered nurse
3.0
6.7
42
191
R5110, ,
SPAT
5.8
6.6
18
36
A02BC02
ATC
pantoprazole; systemic
3.6
6.5
84
566
G04BD08
ATC
solifenacin; oral
7.1
6.4
15
24
H47.0
ICD-10 Finland
Disorders of optic nerve, not elsewhere classified
+∞
6.3
6
*
L04AK02
ATC
teriflunomide; oral
+∞
6.3
6
*
L04AX07
ATC
dimethyl fumarate; oral
+∞
6.3
6
*

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Neurology
13 [38004458]
2.3e+00
3.5e+00
4.3e+00
1.0e+50
4.5e+00
5.1e+00
4.0e+00
cases:39.39%
controls:6.06%
cases:48.48%
controls:2.73%
cases:27.27%
controls:0.51%
cases:76.77%
controls:0.00%
cases:35.35%
controls:0.61%
cases:71.13%
controls:1.43%
cases:78.72%
controls:6.59%
39
60
60
930
48
27
51
963
27
5
72
985
76
0
23
990
35
6
64
984
69
14
28
964
74
62
20
879
Ophthalmology
18 [38004463]
1.6e+00
2.2e+00
4.0e+00
1.0e+50
3.6e+00
2.8e+00
2.0e+00
cases:33.33%
controls:9.39%
cases:29.29%
controls:4.55%
cases:22.22%
controls:0.51%
cases:15.15%
controls:0.00%
cases:23.23%
controls:0.81%
cases:41.24%
controls:3.99%
cases:47.87%
controls:11.05%
33
93
66
897
29
45
70
945
22
5
77
985
15
0
84
990
23
8
76
982
40
39
57
939
45
104
49
837
Emergency Room Visit
ER [9203]
9.5e-01
2.1e+00
3.5e+00
1.0e+50
2.9e+00
1.6e+00
9.8e-01
cases:51.52%
controls:29.19%
cases:45.45%
controls:9.29%
cases:21.21%
controls:0.81%
cases:27.27%
controls:0.00%
cases:13.13%
controls:0.81%
cases:32.99%
controls:9.00%
cases:50.00%
controls:27.31%
51
289
48
701
45
92
54
898
21
8
78
982
27
0
72
990
13
8
86
982
32
88
65
890
47
257
47
684
Outpatient Visit
OP [9202]
8.7e-01
1.3e+00
2.2e+00
—
2.2e+00
2.4e+00
1.6e+00
cases:74.75%
controls:55.45%
cases:68.69%
controls:36.67%
cases:43.43%
controls:7.58%
—
—
cases:45.45%
controls:8.08%
cases:84.54%
controls:33.74%
cases:90.43%
controls:65.99%
74
549
25
441
68
363
31
627
43
75
56
915
—
45
80
54
910
82
330
15
648
85
621
9
320
pregabalin; oral
N02BF02 [955152]
1.7e+00
2.5e+00
—
—
—
2.8e+00
1.8e+00
cases:8.08%
controls:1.62%
cases:8.08%
controls:0.71%
—
—
—
—
—
—
cases:12.37%
controls:0.82%
cases:17.02%
controls:3.40%
8
16
91
974
8
7
91
983
—
—
—
12
8
85
970
16
32
78
909
Inpatient Hospital
21 [8717]
9.1e-01
1.8e+00
1.9e+00
1.0e+50
2.0e+00
1.2e+00
5.0e-01
cases:51.52%
controls:30.00%
cases:37.37%
controls:9.19%
cases:9.09%
controls:1.41%
cases:20.20%
controls:0.00%
cases:12.12%
controls:1.82%
cases:26.80%
controls:9.82%
cases:34.04%
controls:23.80%
51
297
48
693
37
91
62
899
9
14
90
976
20
0
79
990
12
18
87
972
26
96
71
882
32
224
62
717
Examination of eyes and vision
Z01.0 [45566391]
2.2e+00
—
—
—
—
2.7e+00
2.8e+00
cases:7.07%
controls:0.81%
—
—
—
—
—
—
—
—
cases:7.22%
controls:0.51%
cases:15.96%
controls:1.17%
7
8
92
982
—
—
—
—
7
5
90
973
15
11
79
930
Office Visit
OMOP4822458 [581477]
1.3e+00
1.6e+00
—
—
3.2e+00
1.2e+00
1.3e+00
cases:19.19%
controls:6.26%
cases:12.12%
controls:2.83%
—
—
—
—
cases:13.13%
controls:0.61%
cases:11.34%
controls:3.68%
cases:24.47%
controls:8.29%
19
62
80
928
12
28
87
962
—
—
13
6
86
984
11
36
86
942
23
78
71
863
Psychiatry
26 [38004469]
9.2e-01
1.5e+00
1.9e+00
—
2.3e+00
1.6e+00
1.2e+00
cases:13.13%
controls:5.66%
cases:9.09%
controls:2.22%
cases:7.07%
controls:1.11%
—
—
cases:9.09%
controls:1.01%
cases:10.31%
controls:2.25%
cases:18.09%
controls:6.06%
13
56
86
934
9
22
90
968
7
11
92
979
—
9
10
90
980
10
22
87
956
17
57
77
884
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
—
2.8e+00
—
—
—
2.1e+00
1.9e+00
—
—
cases:8.08%
controls:0.51%
—
—
—
—
—
—
cases:6.19%
controls:0.82%
cases:13.83%
controls:2.34%
—
8
5
91
985
—
—
—
6
8
91
970
13
22
81
919
Physiotherapy
R4110 [2001310233]
1.5e+00
2.4e+00
—
—
—
2.1e+00
2.2e+00
cases:7.07%
controls:1.72%
cases:7.07%
controls:0.71%
—
—
—
—
—
—
cases:7.22%
controls:0.92%
cases:13.83%
controls:1.70%
7
17
92
973
7
7
92
983
—
—
—
7
9
90
969
13
16
81
925
prednisolone; oral, parenteral
H02AB06 [21602734]
1.4e+00
1.3e+00
—
—
2.2e+00
1.7e+00
1.4e+00
cases:17.17%
controls:4.95%
cases:9.09%
controls:2.63%
—
—
—
—
cases:6.06%
controls:0.71%
cases:12.37%
controls:2.56%
cases:24.47%
controls:7.65%
17
49
82
941
9
26
90
964
—
—
6
7
93
983
12
25
85
953
23
72
71
869
prednisolone
A07EA01 [21600653]
1.4e+00
1.3e+00
—
—
2.2e+00
1.6e+00
1.4e+00
cases:17.17%
controls:4.95%
cases:9.09%
controls:2.73%
—
—
—
—
cases:6.06%
controls:0.71%
cases:12.37%
controls:2.66%
cases:24.47%
controls:7.65%
17
49
82
941
9
27
90
963
—
—
6
7
93
983
12
26
85
952
23
72
71
869
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
—
2.5e+00
—
—
—
2.4e+00
1.7e+00
—
—
cases:7.07%
controls:0.61%
—
—
—
—
—
—
cases:7.22%
controls:0.72%
cases:9.57%
controls:1.91%
—
7
6
92
984
—
—
—
7
7
90
971
9
18
85
923
azathioprine; oral, parenteral
L04AX01 [21603927]
—
—
—
—
—
3.2e+00
3.2e+00
—
—
—
—
—
—
—
—
—
—
cases:11.34%
controls:0.51%
cases:13.83%
controls:0.64%
—
—
—
—
—
11
5
86
973
13
6
81
935
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
—
2.4e+00
—
—
—
2.2e+00
1.6e+00
—
—
cases:6.06%
controls:0.61%
—
—
—
—
—
—
cases:7.22%
controls:0.82%
cases:10.64%
controls:2.44%
—
6
6
93
984
—
—
—
7
8
90
970
10
23
84
918
Leukocytes [#/volume] in Urine
30405-5 [3018095]
1.3e+00
2.5e+00
—
—
—
1.9e+00
1.4e+00
cases:5.05%
controls:1.41%
cases:7.07%
controls:0.61%
—
—
—
—
—
—
cases:7.22%
controls:1.12%
cases:11.70%
controls:3.08%
5
14
94
976
7
6
92
984
—
—
—
7
11
90
967
11
29
83
912
IgG [Mass/volume] in Serum or Plasma
2465-3 [3005719]
—
2.3e+00
—
—
1.0e+50
—
3.2e+00
—
—
cases:5.05%
controls:0.51%
—
—
—
—
cases:7.07%
controls:0.00%
—
—
cases:11.70%
controls:0.53%
—
5
5
94
985
—
—
7
0
92
990
—
11
5
83
936
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
7.1e-01
1.3e+00
—
—
2.5e+00
1.7e+00
1.3e+00
cases:10.10%
controls:5.25%
cases:8.08%
controls:2.42%
—
—
—
—
cases:6.06%
controls:0.51%
cases:16.49%
controls:3.37%
cases:23.40%
controls:7.86%
10
52
89
938
8
24
91
966
—
—
6
5
93
985
16
33
81
945
22
74
72
867
Case Management Agency
251B00000X [38004193]
5.1e-01
5.7e-01
5.2e-01
3.3e+00
9.8e-01
1.0e+00
7.9e-01
cases:41.41%
controls:29.70%
cases:36.36%
controls:24.44%
cases:16.16%
controls:10.30%
cases:12.12%
controls:0.51%
cases:21.21%
controls:9.19%
cases:50.52%
controls:26.99%
cases:73.40%
controls:55.58%
41
294
58
696
36
242
63
748
16
102
83
888
12
5
87
985
21
91
78
899
49
264
48
714
69
523
25
418
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
R29.8 [45587505]
2.7e+00
—
—
—
—
—
2.5e+00
cases:8.08%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
cases:8.51%
controls:0.74%
8
6
91
984
—
—
—
—
—
8
7
86
934
Other investigative procedure of eye
XCW99 [2001301491]
2.3e+00
—
—
—
—
—
2.6e+00
cases:5.05%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
cases:10.64%
controls:0.85%
5
5
94
985
—
—
—
—
—
10
8
84
933
Outpatient Hospital
22 [8756]
5.4e-01
1.5e+00
—
1.0e+50
2.1e+00
1.2e+00
4.1e-01
cases:33.33%
controls:22.63%
cases:23.23%
controls:6.46%
—
—
cases:10.10%
controls:0.00%
cases:8.08%
controls:1.01%
cases:18.56%
controls:6.24%
cases:25.53%
controls:18.49%
33
224
66
766
23
64
76
926
—
10
0
89
990
8
10
91
980
18
61
79
917
24
174
70
767
Medical doctor
Z2221 [2001311556]
9.1e-01
2.1e+00
—
—
—
2.8e+00
1.1e+00
cases:6.06%
controls:2.53%
cases:6.06%
controls:0.81%
—
—
—
—
—
—
cases:10.31%
controls:0.72%
cases:10.64%
controls:3.72%
6
25
93
965
6
8
93
982
—
—
—
10
7
87
971
10
35
84
906
Bacteria [Presence] in Urine
87829-8 [36304419]
—
2.4e+00
—
—
—
2.2e+00
1.5e+00
—
—
cases:6.06%
controls:0.61%
—
—
—
—
—
—
cases:7.22%
controls:0.82%
cases:7.45%
controls:1.81%
—
6
6
93
984
—
—
—
7
8
90
970
7
17
87
924
Physiotherapist
Z3226 [2001311560]
1.8e+00
—
—
—
—
2.5e+00
2.1e+00
cases:6.06%
controls:1.01%
—
—
—
—
—
—
—
—
cases:8.25%
controls:0.72%
cases:10.64%
controls:1.49%
6
10
93
980
—
—
—
—
8
7
89
971
10
14
84
927
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
4.5e-01
6.3e-01
2.1e+00
—
2.0e+00
1.1e+00
6.2e-01
cases:15.15%
controls:10.20%
cases:12.12%
controls:6.87%
cases:8.08%
controls:1.01%
—
—
cases:11.11%
controls:1.62%
cases:14.43%
controls:5.52%
cases:27.66%
controls:17.11%
15
101
84
889
12
68
87
922
8
10
91
980
—
11
16
88
974
14
54
83
924
26
161
68
780
Basophils/Leukocytes in Blood
30180-4 [3022096]
1.1e+00
1.3e+00
—
—
—
2.3e+00
1.9e+00
cases:7.07%
controls:2.42%
cases:7.07%
controls:2.02%
—
—
—
—
—
—
cases:17.53%
controls:2.15%
cases:23.40%
controls:4.46%
7
24
92
966
7
20
92
970
—
—
—
17
21
80
957
22
42
72
899
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
1.1e+00
1.3e+00
—
—
1.9e+00
2.3e+00
1.9e+00
cases:7.07%
controls:2.53%
cases:7.07%
controls:2.02%
—
—
—
—
cases:5.05%
controls:0.81%
cases:17.53%
controls:2.15%
cases:23.40%
controls:4.46%
7
25
92
965
7
20
92
970
—
—
5
8
94
982
17
21
80
957
22
42
72
899
Monocytes/Leukocytes in Blood
26485-3 [3019069]
1.0e+00
1.3e+00
—
—
1.9e+00
2.3e+00
1.9e+00
cases:7.07%
controls:2.63%
cases:7.07%
controls:2.02%
—
—
—
—
cases:5.05%
controls:0.81%
cases:17.53%
controls:2.15%
cases:23.40%
controls:4.46%
7
26
92
964
7
20
92
970
—
—
5
8
94
982
17
21
80
957
22
42
72
899
Differential panel, method unspecified - Blood
69738-3 [42870588]
—
—
—
—
—
2.1e+00
2.0e+00
—
—
—
—
—
—
—
—
—
—
cases:12.37%
controls:1.74%
cases:18.09%
controls:2.87%
—
—
—
—
—
12
17
85
961
17
27
77
914
Monocytes [#/volume] in Blood
26484-6 [3001604]
1.0e+00
1.3e+00
—
—
1.9e+00
2.3e+00
1.8e+00
cases:7.07%
controls:2.73%
cases:7.07%
controls:2.12%
—
—
—
—
cases:5.05%
controls:0.81%
cases:17.53%
controls:2.04%
cases:23.40%
controls:4.99%
7
27
92
963
7
21
92
969
—
—
5
8
94
982
17
20
80
958
22
47
72
894
Basophils [#/volume] in Blood
26444-0 [3006315]
1.0e+00
1.3e+00
—
—
1.9e+00
2.3e+00
1.8e+00
cases:7.07%
controls:2.73%
cases:7.07%
controls:2.12%
—
—
—
—
cases:5.05%
controls:0.81%
cases:17.53%
controls:2.04%
cases:23.40%
controls:4.99%
7
27
92
963
7
21
92
969
—
—
5
8
94
982
17
20
80
958
22
47
72
894
CBC W Ordered Manual Differential panel - Blood
57782-5 [40760892]
—
—
—
—
—
2.4e+00
1.7e+00
—
—
—
—
—
—
—
—
—
—
cases:8.25%
controls:0.82%
cases:8.51%
controls:1.70%
—
—
—
—
—
8
8
89
970
8
16
86
925
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
1.0e+00
1.4e+00
—
—
1.8e+00
2.3e+00
1.8e+00
cases:7.07%
controls:2.73%
cases:7.07%
controls:1.92%
—
—
—
—
cases:5.05%
controls:0.91%
cases:16.49%
controls:1.94%
cases:23.40%
controls:4.99%
7
27
92
963
7
19
92
971
—
—
5
9
94
981
16
19
81
959
22
47
72
894
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
1.0e+00
1.3e+00
—
—
1.9e+00
2.3e+00
1.8e+00
cases:7.07%
controls:2.73%
cases:7.07%
controls:2.12%
—
—
—
—
cases:5.05%
controls:0.81%
cases:17.53%
controls:2.15%
cases:23.40%
controls:4.89%
7
27
92
963
7
21
92
969
—
—
5
8
94
982
17
21
80
957
22
46
72
895
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
9.6e-01
1.2e+00
—
—
1.8e+00
2.3e+00
1.7e+00
cases:7.07%
controls:2.83%
cases:7.07%
controls:2.22%
—
—
—
—
cases:5.05%
controls:0.91%
cases:17.53%
controls:2.15%
cases:23.40%
controls:5.31%
7
28
92
962
7
22
92
968
—
—
5
9
94
981
17
21
80
957
22
50
72
891
Eosinophils [#/volume] in Blood
26449-9 [3013115]
9.2e-01
1.3e+00
—
—
1.8e+00
2.3e+00
1.7e+00
cases:7.07%
controls:2.93%
cases:7.07%
controls:2.12%
—
—
—
—
cases:5.05%
controls:0.91%
cases:17.53%
controls:2.15%
cases:23.40%
controls:5.31%
7
29
92
961
7
21
92
969
—
—
5
9
94
981
17
21
80
957
22
50
72
891
pantoprazole; oral, parenteral
A02BC02 [21600097]
7.9e-01
1.2e+00
2.0e+00
—
1.7e+00
1.6e+00
1.1e+00
cases:15.15%
controls:7.47%
cases:13.13%
controls:4.24%
cases:5.05%
controls:0.71%
—
—
cases:7.07%
controls:1.31%
cases:16.49%
controls:3.89%
cases:28.72%
controls:12.11%
15
74
84
916
13
42
86
948
5
7
94
983
—
7
13
92
977
16
38
81
940
27
114
67
827
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
3.3e-01
2.6e-01
2.1e+00
—
1.7e+00
5.5e-01
5.6e-01
cases:13.13%
controls:9.80%
cases:9.09%
controls:7.17%
cases:8.08%
controls:1.01%
—
—
cases:9.09%
controls:1.82%
cases:10.31%
controls:6.24%
cases:27.66%
controls:17.96%
13
97
86
893
9
71
90
919
8
10
91
980
—
9
18
90
972
10
61
87
917
26
169
68
772
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
3.7e-01
2.7e-01
2.1e+00
—
1.7e+00
5.8e-01
5.8e-01
cases:13.13%
controls:9.49%
cases:9.09%
controls:7.07%
cases:8.08%
controls:1.01%
—
—
cases:9.09%
controls:1.82%
cases:10.31%
controls:6.03%
cases:27.66%
controls:17.64%
13
94
86
896
9
70
90
920
8
10
91
980
—
9
18
90
972
10
59
87
919
26
166
68
775
Thorax X-ray examination
GD1AA [2001303617]
1.3e+00
1.6e+00
—
—
—
2.4e+00
1.4e+00
cases:7.07%
controls:2.12%
cases:5.05%
controls:1.01%
—
—
—
—
—
—
cases:7.22%
controls:0.72%
cases:15.96%
controls:4.36%
7
21
92
969
5
10
94
980
—
—
—
7
7
90
971
15
41
79
900
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
8.2e-01
8.7e-01
—
—
—
2.1e+00
1.5e+00
cases:7.07%
controls:3.23%
cases:6.06%
controls:2.63%
—
—
—
—
—
—
cases:16.49%
controls:2.45%
cases:22.34%
controls:5.84%
7
32
92
958
6
26
93
964
—
—
—
16
24
81
954
21
55
73
886
Physical Medicine And Rehabilitation
25 [38004468]
1.0e+00
2.1e+00
—
—
—
1.4e+00
1.3e+00
cases:10.10%
controls:3.84%
cases:9.09%
controls:1.21%
—
—
—
—
—
—
cases:6.19%
controls:1.53%
cases:19.15%
controls:5.95%
10
38
89
952
9
12
90
978
—
—
—
6
15
91
963
18
56
76
885
Normoblasts [#/volume] in Blood
715-3 [3021589]
1.3e+00
1.3e+00
—
—
—
1.8e+00
1.6e+00
cases:8.08%
controls:2.42%
cases:7.07%
controls:2.12%
—
—
—
—
—
—
cases:12.37%
controls:2.25%
cases:19.15%
controls:4.68%
8
24
91
966
7
21
92
969
—
—
—
12
22
85
956
18
44
76
897
Extensive MRI examination of brain with high intensity magnet
AA1CG [2001300116]
—
—
—
—
—
—
3.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:11.70%
controls:0.53%
—
—
—
—
—
—
11
5
83
936
calcium (different salts in combination); oral
A12AA20 [21600872]
9.6e-01
1.3e+00
—
—
—
1.8e+00
1.4e+00
cases:7.07%
controls:2.83%
cases:7.07%
controls:2.02%
—
—
—
—
—
—
cases:12.37%
controls:2.35%
cases:17.02%
controls:4.89%
7
28
92
962
7
20
92
970
—
—
—
12
23
85
955
16
46
78
895
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
3.0e-01
2.8e-01
1.7e+00
—
1.4e+00
7.9e-01
5.6e-01
cases:17.17%
controls:13.33%
cases:14.14%
controls:11.11%
cases:10.10%
controls:1.92%
—
—
cases:11.11%
controls:3.03%
cases:19.59%
controls:9.92%
cases:35.11%
controls:23.59%
17
132
82
858
14
110
85
880
10
19
89
971
—
11
30
88
960
19
97
78
881
33
222
61
719
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
3.0e-01
2.8e-01
1.7e+00
—
1.4e+00
7.9e-01
5.5e-01
cases:17.17%
controls:13.33%
cases:14.14%
controls:11.11%
cases:10.10%
controls:1.92%
—
—
cases:11.11%
controls:3.13%
cases:19.59%
controls:9.92%
cases:35.11%
controls:23.70%
17
132
82
858
14
110
85
880
10
19
89
971
—
11
31
88
959
19
97
78
881
33
223
61
718
Platelets [#/volume] in Blood
26515-7 [3007461]
3.0e-01
2.8e-01
1.7e+00
—
1.4e+00
8.1e-01
5.5e-01
cases:17.17%
controls:13.33%
cases:14.14%
controls:11.11%
cases:10.10%
controls:1.92%
—
—
cases:11.11%
controls:3.13%
cases:19.59%
controls:9.82%
cases:35.11%
controls:23.70%
17
132
82
858
14
110
85
880
10
19
89
971
—
11
31
88
959
19
96
78
882
33
223
61
718
MCH [Entitic mass]
28539-5 [3035941]
3.0e-01
2.8e-01
1.7e+00
—
1.4e+00
7.9e-01
5.6e-01
cases:17.17%
controls:13.33%
cases:14.14%
controls:11.11%
cases:10.10%
controls:1.92%
—
—
cases:11.11%
controls:3.13%
cases:19.59%
controls:9.92%
cases:35.11%
controls:23.59%
17
132
82
858
14
110
85
880
10
19
89
971
—
11
31
88
959
19
97
78
881
33
222
61
719
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
3.0e-01
2.8e-01
1.7e+00
—
1.4e+00
7.9e-01
5.5e-01
cases:17.17%
controls:13.33%
cases:14.14%
controls:11.11%
cases:10.10%
controls:1.92%
—
—
cases:11.11%
controls:3.13%
cases:19.59%
controls:9.92%
cases:35.11%
controls:23.70%
17
132
82
858
14
110
85
880
10
19
89
971
—
11
31
88
959
19
97
78
881
33
223
61
718
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
3.0e-01
2.8e-01
1.7e+00
—
1.4e+00
7.9e-01
5.5e-01
cases:17.17%
controls:13.33%
cases:14.14%
controls:11.11%
cases:10.10%
controls:1.92%
—
—
cases:11.11%
controls:3.13%
cases:19.59%
controls:9.92%
cases:35.11%
controls:23.80%
17
132
82
858
14
110
85
880
10
19
89
971
—
11
31
88
959
19
97
78
881
33
224
61
717
Leukocytes [#/volume] in Blood
26464-8 [3010813]
3.0e-01
2.6e-01
1.7e+00
—
1.4e+00
7.9e-01
5.7e-01
cases:17.17%
controls:13.33%
cases:14.14%
controls:11.31%
cases:10.10%
controls:1.92%
—
—
cases:11.11%
controls:3.13%
cases:19.59%
controls:9.92%
cases:35.11%
controls:23.49%
17
132
82
858
14
112
85
878
10
19
89
971
—
11
31
88
959
19
97
78
881
33
221
61
720
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
5.4e-01
1.2e+00
—
—
—
1.8e+00
1.2e+00
cases:8.08%
controls:4.85%
cases:8.08%
controls:2.53%
—
—
—
—
—
—
cases:15.46%
controls:2.97%
cases:21.28%
controls:7.23%
8
48
91
942
8
25
91
965
—
—
—
15
29
82
949
20
68
74
873
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
2.6e-01
3.7e-01
1.8e+00
—
1.7e+00
1.2e+00
6.8e-01
cases:13.13%
controls:10.40%
cases:10.10%
controls:7.17%
cases:6.06%
controls:1.01%
—
—
cases:9.09%
controls:1.72%
cases:19.59%
controls:6.54%
cases:31.91%
controls:19.13%
13
103
86
887
10
71
89
919
6
10
93
980
—
9
17
90
973
19
64
78
914
30
180
64
761
Perimetry
XCK00 [2001301380]
—
—
—
—
—
—
3.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:12.77%
controls:0.74%
—
—
—
—
—
—
12
7
82
934
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
8.3e-01
1.2e+00
—
—
—
4.2e-01
8.3e-01
cases:26.26%
controls:13.43%
cases:20.20%
controls:7.07%
—
—
—
—
—
—
cases:12.37%
controls:8.49%
cases:44.68%
controls:26.04%
26
133
73
857
20
70
79
920
—
—
—
12
83
85
895
42
245
52
696
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
4.2e-01
3.7e-01
1.7e+00
—
1.4e+00
9.8e-01
5.1e-01
cases:15.15%
controls:10.51%
cases:12.12%
controls:8.69%
cases:8.08%
controls:1.52%
—
—
cases:9.09%
controls:2.32%
cases:18.56%
controls:7.87%
cases:29.79%
controls:20.30%
15
104
84
886
12
86
87
904
8
15
91
975
—
9
23
90
967
18
77
79
901
28
191
66
750
Limited function/disability (L)
L28 [2002000647]
—
—
—
—
—
—
2.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.51%
controls:0.64%
—
—
—
—
—
—
8
6
86
935
Ocular pain
H57.1 [45596140]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.38%
controls:0.53%
—
—
—
—
—
—
6
5
88
936
Paraesthesia of skin
R20.2 [45568120]
2.5e+00
—
—
—
—
—
—
cases:6.06%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
—
—
6
5
93
985
—
—
—
—
—
—
Intravenous
ZX120 [2001311495]
2.5e+00
—
—
—
—
—
—
cases:7.07%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
—
—
7
6
92
984
—
—
—
—
—
—
aPTT in Platelet poor plasma by Coagulation assay
14979-9 [3018677]
—
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.38%
controls:0.64%
—
—
—
—
—
—
6
6
88
935
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
—
2.4e+00
—
—
—
—
1.7e+00
—
—
cases:6.06%
controls:0.61%
—
—
—
—
—
—
—
—
cases:6.38%
controls:1.17%
—
6
6
93
984
—
—
—
—
6
11
88
930
Nuclear Ab [Titer] in Serum
29953-7 [3037522]
2.4e+00
—
—
—
—
—
1.8e+00
cases:6.06%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
cases:5.32%
controls:0.96%
6
6
93
984
—
—
—
—
—
5
9
89
932
Implementation of physical therapy rehabilitation plan
SPAT1223 [2001700324]
1.6e+00
—
—
—
—
2.4e+00
1.1e+00
cases:6.06%
controls:1.31%
—
—
—
—
—
—
—
—
cases:5.15%
controls:0.51%
cases:5.32%
controls:1.91%
6
13
93
977
—
—
—
—
5
5
92
973
5
18
89
923
Borrelia burgdorferi IgM Ab [Units/volume] in Serum
7818-8 [3008230]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.32%
controls:0.53%
—
—
—
—
—
—
5
5
89
936
Bacteria identified in Isolate by Culture
43409-2 [3042936]
-1.0e+50
—
—
—
—
—
2.3e+00
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
cases:5.32%
controls:0.53%
0
7
99
983
—
—
—
—
—
5
5
89
936
Dry eye syndrome
H04.10 [2000502254]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.32%
controls:0.53%
—
—
—
—
—
—
5
5
89
936
Limited function/disability NOS
A28 [2002000162]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.32%
controls:0.53%
—
—
—
—
—
—
5
5
89
936
Nursing episode
950 [44777714]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.32%
controls:0.53%
—
—
—
—
—
—
5
5
89
936
Social worker
Z2446 [2001311559]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.32%
controls:0.53%
—
—
—
—
—
—
5
5
89
936
Urgent procedure
ZXD05 [2001311386]
9.4e-01
2.3e+00
—
—
—
1.9e+00
4.0e-01
cases:9.09%
controls:3.74%
cases:5.05%
controls:0.51%
—
—
—
—
—
—
cases:6.19%
controls:1.02%
cases:5.32%
controls:3.61%
9
37
90
953
5
5
94
985
—
—
—
6
10
91
968
5
34
89
907
Osmolality of Urine
2695-5 [3026782]
1.6e+00
2.3e+00
—
—
—
—
2.0e+00
cases:5.05%
controls:1.11%
cases:5.05%
controls:0.51%
—
—
—
—
—
—
—
—
cases:5.32%
controls:0.74%
5
11
94
979
5
5
94
985
—
—
—
—
5
7
89
934
Infectious Disease
44 [38004484]
2.3e+00
—
—
—
—
—
—
cases:5.05%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
—
—
5
5
94
985
—
—
—
—
—
—
Pharmacy visit
OMOP4822462 [581458]
2.2e-01
8.5e-01
1.1e+00
1.6e+00
1.0e+00
7.8e-01
1.7e+00
cases:91.92%
controls:90.10%
cases:86.87%
controls:73.84%
cases:55.56%
controls:28.99%
cases:5.05%
controls:1.01%
cases:55.56%
controls:31.31%
cases:87.63%
controls:76.48%
cases:98.94%
controls:94.47%
91
892
8
98
86
731
13
259
55
287
44
703
5
10
94
980
55
310
44
680
85
748
12
230
93
889
1
52
Bacteria identified in Urine by Culture
630-4 [3026008]
-1.0e+50
—
—
—
—
—
2.0e+00
cases:0.00%
controls:1.41%
—
—
—
—
—
—
—
—
—
—
cases:13.83%
controls:2.02%
0
14
99
976
—
—
—
—
—
13
19
81
922
gabapentin; oral
N02BF01 [955005]
1.9e+00
—
—
—
—
—
2.0e+00
cases:6.06%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
cases:10.64%
controls:1.59%
6
9
93
981
—
—
—
—
—
10
15
84
926
Other specified special examinations
Z01.8 [45581003]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.64%
controls:1.59%
—
—
—
—
—
—
10
15
84
926
ibuprofen; oral, parenteral, rectal
M01AE01 [21603967]
4.7e-01
1.0e+00
—
—
1.5e+00
8.5e-01
4.5e-01
cases:39.39%
controls:28.89%
cases:30.30%
controls:13.54%
—
—
—
—
cases:6.06%
controls:1.41%
cases:28.87%
controls:14.83%
cases:51.06%
controls:39.96%
39
286
60
704
30
134
69
856
—
—
6
14
93
976
28
145
69
833
48
376
46
565
ibuprofen
R02AX02 [1588667]
4.7e-01
1.0e+00
—
—
1.5e+00
8.5e-01
4.5e-01
cases:39.39%
controls:28.89%
cases:30.30%
controls:13.54%
—
—
—
—
cases:6.06%
controls:1.41%
cases:28.87%
controls:14.83%
cases:51.06%
controls:39.96%
39
286
60
704
30
134
69
856
—
—
6
14
93
976
28
145
69
833
48
376
46
565
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
3.3e-01
1.8e-01
1.6e+00
—
1.8e+00
9.2e-01
7.1e-01
cases:11.11%
controls:8.28%
cases:7.07%
controls:5.96%
cases:7.07%
controls:1.52%
—
—
cases:9.09%
controls:1.62%
cases:13.40%
controls:5.83%
cases:25.53%
controls:14.45%
11
82
88
908
7
59
92
931
7
15
92
975
—
9
16
90
974
13
57
84
921
24
136
70
805
IgA [Mass/volume] in Serum or Plasma
2458-8 [3007164]
—
—
—
—
—
—
1.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.57%
controls:1.81%
—
—
—
—
—
—
9
17
85
924
Telehealth
OMOP5556618 [722455]
3.9e-01
1.2e+00
—
—
—
1.7e+00
4.3e-01
cases:13.13%
controls:9.29%
cases:10.10%
controls:3.13%
—
—
—
—
—
—
cases:16.49%
controls:3.58%
cases:21.28%
controls:14.98%
13
92
86
898
10
31
89
959
—
—
—
16
35
81
943
20
141
74
800
Short blood count panel - Blood
55429-5 [40758558]
—
—
—
—
-1.0e+50
1.4e+00
1.6e+00
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
cases:5.15%
controls:1.33%
cases:10.64%
controls:2.23%
—
—
—
—
0
5
99
985
5
13
92
965
10
21
84
920
esomeprazole; oral, parenteral
A02BC05 [21600100]
8.3e-01
1.6e+00
—
—
—
1.4e+00
7.2e-01
cases:12.12%
controls:5.66%
cases:10.10%
controls:2.12%
—
—
—
—
—
—
cases:9.28%
controls:2.56%
cases:11.70%
controls:6.06%
12
56
87
934
10
21
89
969
—
—
—
9
25
88
953
11
57
83
884
amitriptyline; oral, parenteral
N06AA09 [21604696]
1.6e+00
1.4e+00
—
—
—
—
1.0e+00
cases:9.09%
controls:1.92%
cases:6.06%
controls:1.62%
—
—
—
—
—
—
—
—
cases:8.51%
controls:3.29%
9
19
90
971
6
16
93
974
—
—
—
—
8
31
86
910
More than one and less than three hours
ZXE10 [2001311401]
1.2e+00
2.2e+00
—
—
—
2.2e+00
1.6e+00
cases:9.09%
controls:2.93%
cases:5.05%
controls:0.61%
—
—
—
—
—
—
cases:5.15%
controls:0.61%
cases:11.70%
controls:2.66%
9
29
90
961
5
6
94
984
—
—
—
5
6
92
972
11
25
83
916
Emergency Room and Inpatient Visit
ERIP [262]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:11.70%
controls:2.66%
—
—
—
—
—
—
11
25
83
916
Erythrocytes [Presence] in Urine by Automated
53292-9 [3041096]
1.3e+00
—
—
—
—
—
1.6e+00
cases:6.06%
controls:1.72%
—
—
—
—
—
—
—
—
—
—
cases:10.64%
controls:2.44%
6
17
93
973
—
—
—
—
—
10
23
84
918
Home Visit
OMOP4822459 [581476]
—
—
—
—
—
2.0e+00
1.5e+00
—
—
—
—
—
—
—
—
—
—
cases:5.15%
controls:0.72%
cases:9.57%
controls:2.23%
—
—
—
—
—
5
7
92
971
9
21
85
920
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
—
—
—
—
—
—
1.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:11.70%
controls:2.87%
—
—
—
—
—
—
11
27
83
914
INR in Blood by Coagulation assay
34714-6 [3032080]
—
1.2e+00
—
—
—
—
1.5e+00
—
—
cases:5.05%
controls:1.62%
—
—
—
—
—
—
—
—
cases:12.77%
controls:3.29%
—
5
16
94
974
—
—
—
—
12
31
82
910
omeprazole; oral, parenteral
A02BC01 [21600096]
1.4e+00
—
—
—
—
—
4.4e-01
cases:10.10%
controls:2.63%
—
—
—
—
—
—
—
—
—
—
cases:5.32%
controls:3.51%
10
26
89
964
—
—
—
—
—
5
33
89
908
Other and unspecified abdominal pain
R10.4 [45568113]
9.7e-01
—
—
—
—
—
1.3e+00
cases:12.12%
controls:4.95%
—
—
—
—
—
—
—
—
—
—
cases:13.83%
controls:4.14%
12
49
87
941
—
—
—
—
—
13
39
81
902
Gastroenterology
10 [38004455]
1.0e+00
—
—
—
—
—
1.3e+00
cases:7.07%
controls:2.63%
—
—
—
—
—
—
—
—
—
—
cases:12.77%
controls:3.93%
7
26
92
964
—
—
—
—
—
12
37
82
904
azithromycin; oral, parenteral
J01FA10 [21602978]
7.2e-01
—
—
—
—
1.2e+00
7.4e-01
cases:23.23%
controls:12.83%
—
—
—
—
—
—
—
—
cases:13.40%
controls:4.29%
cases:22.34%
controls:12.11%
23
127
76
863
—
—
—
—
13
42
84
936
21
114
73
827
Laboratory Visit
OMOP4822461 [32036]
1.8e-01
1.6e-01
1.2e+00
—
7.8e-01
4.4e-01
3.7e-01
cases:17.17%
controls:14.75%
cases:17.17%
controls:15.05%
cases:14.14%
controls:4.65%
—
—
cases:12.12%
controls:5.96%
cases:21.65%
controls:15.13%
cases:36.17%
controls:28.06%
17
146
82
844
17
149
82
841
14
46
85
944
—
12
59
87
931
21
148
76
830
34
264
60
677
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
6.9e-01
—
—
—
—
8.4e-01
1.2e+00
cases:6.06%
controls:3.13%
—
—
—
—
—
—
—
—
cases:6.19%
controls:2.76%
cases:17.02%
controls:5.84%
6
31
93
959
—
—
—
—
6
27
91
951
16
55
78
886
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
6.9e-01
—
—
—
—
8.4e-01
1.2e+00
cases:6.06%
controls:3.13%
—
—
—
—
—
—
—
—
cases:6.19%
controls:2.76%
cases:17.02%
controls:5.84%
6
31
93
959
—
—
—
—
6
27
91
951
16
55
78
886
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
6.6e-01
—
—
—
—
8.0e-01
1.2e+00
cases:6.06%
controls:3.23%
—
—
—
—
—
—
—
—
cases:6.19%
controls:2.86%
cases:17.02%
controls:5.95%
6
32
93
958
—
—
—
—
6
28
91
950
16
56
78
885
25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
68438-1 [40771025]
7.2e-01
1.3e+00
—
—
—
—
1.1e+00
cases:5.05%
controls:2.53%
cases:6.06%
controls:1.72%
—
—
—
—
—
—
—
—
cases:13.83%
controls:4.89%
5
25
94
965
6
17
93
973
—
—
—
—
13
46
81
895
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
5.9e-01
7.0e-01
1.7e+00
—
1.6e+00
1.1e+00
4.7e-01
cases:12.12%
controls:7.07%
cases:11.11%
controls:5.86%
cases:6.06%
controls:1.21%
—
—
cases:7.07%
controls:1.52%
cases:15.46%
controls:5.62%
cases:20.21%
controls:13.71%
12
70
87
920
11
58
88
932
6
12
93
978
—
7
15
92
975
15
55
82
923
19
129
75
812
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
5.0e-01
3.4e-01
—
—
—
1.0e+00
1.1e+00
cases:8.08%
controls:5.05%
cases:5.05%
controls:3.64%
—
—
—
—
—
—
cases:10.31%
controls:3.89%
cases:22.34%
controls:8.82%
8
50
91
940
5
36
94
954
—
—
—
10
38
87
940
21
83
73
858
Emergency Medicine
93 [38004510]
5.1e-01
9.5e-01
—
—
—
—
9.8e-01
cases:6.06%
controls:3.74%
cases:6.06%
controls:2.42%
—
—
—
—
—
—
—
—
cases:19.15%
controls:8.18%
6
37
93
953
6
24
93
966
—
—
—
—
18
77
76
864
Supplier / Service Provider
OMOP5117446 [33004]
-1.4e+00
—
—
—
—
—
2.2e+00
cases:8.08%
controls:26.97%
—
—
—
—
—
—
—
—
—
—
cases:7.45%
controls:0.85%
8
267
91
723
—
—
—
—
—
7
8
87
933
Transferrin.carbohydrate deficient.disialo/Transferrin.total in Serum or Plasma
21573-1 [3003031]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
0
5
99
985
—
—
—
—
0
6
97
972
—
Acute pharyngitis, unspecified
J02.9 [45538472]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
0
7
94
934
Ultrasound examination of paranasal sinuses
SPAT1028 [2001700129]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.85%
0
7
99
983
—
—
—
—
—
0
8
94
933
candesartan; oral
C09CA06 [21601829]
—
—
—
—
-1.0e+50
-1.0e+50
8.9e-02
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
cases:0.00%
controls:2.56%
cases:5.32%
controls:4.89%
—
—
—
—
0
7
99
983
0
25
97
953
5
46
89
895
prednisolone
S01BA04 [21603621]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.32%
controls:0.64%
—
—
—
—
—
—
5
6
89
935
insulin glulisine; parenteral
A10AB06 [21600720]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
0
5
94
936
Pulmonary Disease
29 [38004472]
1.1e+00
1.4e+00
—
—
-1.0e+50
1.2e+00
8.9e-01
cases:10.10%
controls:3.54%
cases:6.06%
controls:1.52%
—
—
—
—
cases:0.00%
controls:0.51%
cases:5.15%
controls:1.53%
cases:10.64%
controls:4.68%
10
35
89
955
6
15
93
975
—
—
0
5
99
985
5
15
92
963
10
44
84
897
Myelin oligodendrocyte glycoprotein Ab [Titer] in Serum by Cell binding immunofluorescent assay
91544-7 [37020271]
—
—
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.32%
controls:0.00%
—
—
—
—
—
—
5
0
89
941
Degeneration of macula and posterior pole
H35.39 [2000502319]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
0
6
94
935
Caries of dentine
K02.1 [45548134]
-2.2e-01
—
-1.0e+50
—
—
1.1e+00
3.7e-01
cases:6.06%
controls:7.47%
—
—
cases:0.00%
controls:0.51%
—
—
—
—
cases:7.22%
controls:2.56%
cases:17.02%
controls:12.43%
6
74
93
916
—
0
5
99
985
—
—
7
25
90
953
16
117
78
824
itraconazole; oral, parenteral
J02AC02 [21603081]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.49%
—
—
—
—
—
—
0
14
94
927
Maternal care for excessive fetal growth
O36.6 [45543983]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.52%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.96%
0
15
99
975
—
—
—
—
—
0
9
94
932
nitrofurantoin; oral
J01XE01 [21603058]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
—
0
5
99
985
—
—
—
—
—
Guidance concerning treatment of rash and skin
SPAT1156 [2001700257]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
99
982
—
—
—
—
—
—
Other and unspecified skin changes
R23.8 [45573020]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
99
983
—
—
—
—
—
—
interferon beta-1b; parenteral
L03AB08 [21603865]
—
—
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.38%
controls:0.00%
—
—
—
—
—
—
6
0
88
941
hydroxyzine; oral, parenteral
N05BB01 [21604590]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.28%
—
—
—
—
—
—
0
12
94
929
flumetasone and antiinfectives
S02CA02 [21605174]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
0
5
94
936
Thyroxine (T4) free [Moles/volume] in Serum or Plasma
14920-3 [3008486]
7.0e-02
7.1e-01
—
—
—
—
1.7e-01
cases:8.08%
controls:7.58%
cases:8.08%
controls:4.14%
—
—
—
—
—
—
—
—
cases:13.83%
controls:11.90%
8
75
91
915
8
41
91
949
—
—
—
—
13
112
81
829
Knee X-ray examination without contrast
NG1AA [2001308049]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
0
7
94
934
betamethasone
D07AC01 [21602120]
5.7e-01
—
—
—
—
-1.0e+50
5.5e-01
cases:7.07%
controls:4.14%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.64%
cases:9.57%
controls:5.74%
7
41
92
949
—
—
—
—
0
16
97
962
9
54
85
887
Other and unspecified symptoms and signs involving cognitive functions and awareness
R41.8 [45534452]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
0
5
94
936
etodolac; oral
M01AB08 [21603948]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
99
980
—
—
—
—
—
—
Acute bronchitis
J20 [45581849]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.28%
—
—
—
—
—
—
0
12
94
929
Other specified pulpit
K04.08 [2000502703]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
0
5
99
985
—
—
—
—
—
0
5
94
936
tamoxifen; oral
L02BA01 [21603831]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
0
8
94
933
rabeprazole; oral
A02BC04 [21600099]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
0
5
99
985
—
—
—
—
—
0
7
94
934
ketoprofen; oral, parenteral, rectal
M01AE03 [21603969]
7.9e-01
1.6e+00
—
—
—
—
—
cases:10.10%
controls:4.85%
cases:5.05%
controls:1.11%
—
—
—
—
—
—
—
—
—
—
10
48
89
942
5
11
94
979
—
—
—
—
—
Treatment-related counselling outside office
SPAT1249 [2001700350]
6.9e-01
—
—
—
—
2.0e+00
6.4e-01
cases:6.06%
controls:3.13%
—
—
—
—
—
—
—
—
cases:5.15%
controls:0.72%
cases:8.51%
controls:4.68%
6
31
93
959
—
—
—
—
5
7
92
971
8
44
86
897
Contact with and exposure to other communicable diseases
Z20.8 [45542410]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
0
9
94
932
CD3-CD19+ cells/cells in Blood
15196-9 [3006245]
—
—
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.32%
controls:0.00%
—
—
—
—
—
—
5
0
89
941
Cough
R05 [2002000886]
—
—
—
—
—
—
1.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.45%
controls:2.55%
—
—
—
—
—
—
7
24
87
917
Therapeutic discussion
SPAT1240 [2001700341]
-1.0e+50
—
—
—
—
—
1.5e+00
cases:0.00%
controls:1.11%
—
—
—
—
—
—
—
—
—
—
cases:5.32%
controls:1.28%
0
11
99
979
—
—
—
—
—
5
12
89
929
codeine and paracetamol
N02AJ06 [1123647]
-4.1e-02
—
—
—
—
9.6e-01
5.5e-01
cases:5.05%
controls:5.25%
—
—
—
—
—
—
—
—
cases:6.19%
controls:2.45%
cases:20.21%
controls:12.75%
5
52
94
938
—
—
—
—
6
24
91
954
19
120
75
821
Obstetric epidural analgesia
WX307 [2001310797]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
0
7
94
934
Handing over of treatment supplies
SPAT1262 [2001700363]
—
—
-1.0e+50
—
—
—
7.9e-01
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
cases:7.45%
controls:3.51%
—
—
0
5
99
985
—
—
—
7
33
87
908
Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection
6357-8 [3024950]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
0
7
99
983
—
—
—
—
—
Moderate depressive episode
F32.1 [45552478]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
0
5
94
936
levocetirizine; oral
R06AE09 [21603498]
—
-1.0e+50
—
—
—
—
7.2e-01
—
—
cases:0.00%
controls:1.41%
—
—
—
—
—
—
—
—
cases:5.32%
controls:2.66%
—
0
14
99
976
—
—
—
—
5
25
89
916
Acute inflammatory disease of uterus
N71.0 [45596880]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
99
985
—
—
—
—
—
—
Leukocyte esterase [Presence] in Urine by Automated test strip
60026-2 [40763086]
8.3e-01
—
—
—
—
1.0e+00
1.0e+00
cases:6.06%
controls:2.73%
—
—
—
—
—
—
—
—
cases:6.19%
controls:2.35%
cases:11.70%
controls:4.46%
6
27
93
963
—
—
—
—
6
23
91
955
11
42
83
899
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]
4.4e-01
1.0e+00
—
—
—
1.5e+00
5.2e-01
cases:9.09%
controls:6.06%
cases:7.07%
controls:2.73%
—
—
—
—
—
—
cases:9.28%
controls:2.25%
cases:13.83%
controls:8.71%
9
60
90
930
7
27
92
963
—
—
—
9
22
88
956
13
82
81
859
phenylpropanolamine, combinations; oral
R01BA51 [21603212]
9.5e-01
—
—
—
—
—
—
cases:6.06%
controls:2.42%
—
—
—
—
—
—
—
—
—
—
—
—
6
24
93
966
—
—
—
—
—
—
Trisomy 21 risk [Likelihood] in Fetus
43995-0 [3043238]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
99
985
—
—
—
—
—
—
Phakoemulsification with implantation of artificial lens in posterior chamber
CJE20 [2001301342]
—
—
—
—
—
—
1.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.32%
controls:1.59%
—
—
—
—
—
—
5
15
89
926
Other removal of retained products of conception after delivery or abortion
MBA96 [2001306937]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
99
985
—
—
—
—
—
—
insulin detemir; parenteral
A10AE05 [21600740]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.82%
cases:0.00%
controls:1.41%
—
—
—
—
—
—
cases:0.00%
controls:1.43%
cases:0.00%
controls:2.66%
0
18
99
972
0
14
99
976
—
—
—
0
14
97
964
0
25
94
916
Treatment plan or consultation
WZC00 [2001310885]
8.7e-01
-1.0e+50
—
—
—
—
4.3e-01
cases:6.06%
controls:2.63%
cases:0.00%
controls:1.11%
—
—
—
—
—
—
—
—
cases:6.38%
controls:4.25%
6
26
93
964
0
11
99
979
—
—
—
—
6
40
88
901
Person consulting for explanation of investigation findings
Z71.2 [45552100]
1.2e+00
—
—
—
—
—
1.4e+00
cases:5.05%
controls:1.52%
—
—
—
—
—
—
—
—
—
—
cases:9.57%
controls:2.55%
5
15
94
975
—
—
—
—
—
9
24
85
917
dexrabeprazole
A02BC07 [45893509]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
0
5
99
985
—
—
—
—
—
0
7
94
934
Very demanding periodontal treatment
SDA05 [2001310330]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
0
5
94
936
ketotifen
S01GX08 [21605092]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
0
5
99
985
—
—
—
—
—
0
5
94
936
fusidic acid
S01AA13 [21603564]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.01%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
0
10
99
980
—
—
—
—
—
0
7
94
934
Other administrative function
SPAT1281 [2001700382]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
0
5
99
985
—
—
—
—
—
0
5
94
936
Detailed morfological ultrasound examination of fetus
MA2HE [2001306836]
4.0e-01
—
—
—
—
—
—
cases:5.05%
controls:3.43%
—
—
—
—
—
—
—
—
—
—
—
—
5
34
94
956
—
—
—
—
—
—
Other minor procedure in surgery of teeth, jaws, mouth and pharynx
TEW99 [2001302349]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
0
6
94
935
clidinium and psycholeptics
A03CA02 [21600204]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
0
5
97
973
—
tranexamic acid; oral, parenteral
B02AA02 [21601036]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
0
7
99
983
—
—
—
—
—
candesartan and diuretics
C09DA06 [21601838]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.81%
cases:0.00%
controls:1.01%
—
—
—
—
—
—
cases:0.00%
controls:1.12%
cases:0.00%
controls:1.49%
0
8
99
982
0
10
99
980
—
—
—
0
11
97
967
0
14
94
927
Fetal Trisomy 21 risk [Likelihood] Based on maternal age
49090-4 [3049207]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
99
984
—
—
—
—
—
—
Loss of teeth due to accident, extraction or local periodontal disease
K08.1 [45591573]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
0
7
94
934
hydrocortisone
C05AA01 [21601608]
3.3e-01
—
—
—
—
—
3.1e-01
cases:8.08%
controls:5.96%
—
—
—
—
—
—
—
—
—
—
cases:6.38%
controls:4.78%
8
59
91
931
—
—
—
—
—
6
45
88
896
glatiramer acetate; parenteral
L03AX13 [21603886]
1.0e+50
1.0e+50
—
—
—
—
1.0e+50
cases:5.05%
controls:0.00%
cases:6.06%
controls:0.00%
—
—
—
—
—
—
—
—
cases:14.89%
controls:0.00%
5
0
94
990
6
0
93
990
—
—
—
—
14
0
80
941
Extraction of tooth
EBA00 [2001301923]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.12%
—
—
—
—
—
—
—
0
11
97
967
—
fexofenadine; oral
R06AX26 [21603525]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
0
7
99
983
—
—
—
—
0
6
94
935
Eye symptom/complaint other
F29 [2002000412]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
99
985
—
—
—
—
—
—
rofecoxib; oral
M01AH02 [21603993]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
0
7
94
934
Personal history of diseases of the digestive system
Z87.1 [45542474]
—
—
—
—
—
—
1.9e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.38%
controls:5.31%
—
—
—
—
—
—
6
50
88
891
Cytology report of Cervical or vaginal smear or scraping Cyto stain
47528-5 [3050380]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
0
8
94
933
Troponin I.cardiac [Mass/volume] in Serum or Plasma
10839-9 [3021337]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
0
5
97
973
—
Other medical or dental certificate
WZA90 [2001310883]
-1.0e+50
—
—
—
—
—
1.1e+00
cases:0.00%
controls:2.02%
—
—
—
—
—
—
—
—
—
—
cases:5.32%
controls:1.81%
0
20
99
970
—
—
—
—
—
5
17
89
924
Type 1 diabetes mellitus, With ketoacidosis
E10.1 [45542735]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
99
985
—
—
—
—
—
—
Clinical Cytogenetics and Genomics
OMOP4822000 [32411]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
99
981
—
—
—
—
—
—
Influenza virus A RNA [Presence] in Specimen by NAA with probe detection
34487-9 [3044938]
—
—
—
—
—
—
1.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.32%
controls:1.49%
—
—
—
—
—
—
5
14
89
927
Acute bronchitis, unspecified
J20.9 [45562445]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
99
983
—
—
—
—
—
—
chlorphenamine, combinations
R06AB54 [21603468]
5.9e-01
-1.0e+50
—
—
—
—
—
cases:6.06%
controls:3.43%
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
6
34
93
956
0
5
99
985
—
—
—
—
—
Proliferative diabetic retinopathy and Type 1 diabetes mellitus, With ophthalmic complications
H36.03*E10.3 [2000503982]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
cases:0.00%
controls:0.85%
0
5
99
985
—
—
—
—
0
5
97
973
0
8
94
933
pH of Urine
2756-5 [3015736]
—
—
—
—
—
—
7.0e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.57%
controls:4.99%
—
—
—
—
—
—
9
47
85
894
Opening and preparing the root canals
SGA02 [2001310380]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.49%
—
—
—
—
—
—
0
14
94
927
pH of Serum or Plasma
2753-2 [3018418]
—
—
—
—
—
—
5.3e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.32%
controls:3.19%
—
—
—
—
—
—
5
30
89
911
telmisartan and diuretics
C09DA07 [21601839]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.71%
cases:0.00%
controls:0.51%
—
—
—
—
—
—
cases:0.00%
controls:0.61%
cases:0.00%
controls:0.64%
0
7
99
983
0
5
99
985
—
—
—
0
6
97
972
0
6
94
935
Erysipelas
A46 [45561706]
-1.0e+50
—
—
—
—
—
1.6e+00
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
cases:5.32%
controls:1.17%
0
7
99
983
—
—
—
—
—
5
11
89
930
Apolipoprotein A-I [Mass/volume] in Serum or Plasma
1869-7 [3008364]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
0
5
94
936
Chronic gingivitis
K05.1 [45605912]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
0
5
94
936
Excessive and frequent menstruation with regular cycle
N92.0 [45577544]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
0
5
97
973
—
Trisomy 18 risk [Likelihood] in Fetus
43994-3 [3047352]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
99
985
—
—
—
—
—
—
Examination for driving licence
Z02.4 [45552056]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.06%
—
—
—
—
—
—
0
10
94
931
mirtazapine; oral
N06AX11 [21604740]
1.0e+00
—
—
—
—
—
7.0e-01
cases:8.08%
controls:3.03%
—
—
—
—
—
—
—
—
—
—
cases:9.57%
controls:4.99%
8
30
91
960
—
—
—
—
—
9
47
85
894
Preventive oral health care
SCA02 [2001310303]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.17%
0
5
99
985
—
—
—
—
—
0
11
94
930
hydroxyethylpromethazine, combinations
R06AD55 [21603490]
9.5e-01
—
—
—
—
—
—
cases:6.06%
controls:2.42%
—
—
—
—
—
—
—
—
—
—
—
—
6
24
93
966
—
—
—
—
—
—
mirabegron; oral
G04BD12 [43534790]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
99
985
—
—
—
—
—
—
Incontinence urine
U04 [2002001139]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
0
5
94
936
azelastine; nasal
R01AC03 [21605035]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
0
8
97
970
—
citalopram; oral, parenteral
N06AB04 [21604712]
—
—
—
—
-1.0e+50
—
1.1e+00
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
cases:9.57%
controls:3.51%
—
—
—
—
0
6
99
984
—
9
33
85
908
Emergency visit or other similar visit involving procedures
WYA05 [2001310871]
—
-1.0e+50
—
—
—
1.8e+00
4.3e-01
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
cases:6.19%
controls:1.12%
cases:11.70%
controls:7.97%
—
0
12
99
978
—
—
—
6
11
91
967
11
75
83
866
Other blockage of nerve
WX290 [2001310792]
—
—
—
—
—
1.2e+00
1.5e-01
—
—
—
—
—
—
—
—
—
—
cases:5.15%
controls:1.64%
cases:8.51%
controls:7.44%
—
—
—
—
—
5
16
92
962
8
70
86
871
methylprednisolone; oral, parenteral
H02AB04 [21602732]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.32%
controls:1.17%
—
—
—
—
—
—
5
11
89
930
Uncompl labour/delivery livebirth
W90 [2002001277]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
0
5
94
936
Malaise and fatigue
R53 [45553741]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.38%
controls:1.59%
—
—
—
—
—
—
6
15
88
926
Insulin-dependent diabetes diabetic hypoglycemic coma
E10.00 [2000501424]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
0
5
99
985
—
—
—
—
—
0
5
94
936
Surveillance of contraceptive drugs
Z30.4 [45547299]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
0
8
94
933
Sterilization
Z30.2 [45609921]
—
—
—
—
—
—
1.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.32%
controls:1.28%
—
—
—
—
—
—
5
12
89
929
mometasone, combinations
R01AD59 [947911]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
0
5
94
936
ABO and Rh group [Type] in Blood
882-1 [3003694]
—
-1.0e+50
—
—
—
—
9.5e-01
—
—
cases:0.00%
controls:1.11%
—
—
—
—
—
—
—
—
cases:5.32%
controls:2.13%
—
0
11
99
979
—
—
—
—
5
20
89
921
Sinusitis acute/chronic
R75 [2002000943]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
0
6
99
984
—
—
—
—
—
0
6
94
935
Creatinine [Moles/volume] in Urine
14683-7 [3009508]
—
—
—
—
—
1.6e+00
3.7e-01
—
—
—
—
—
—
—
—
—
—
cases:5.15%
controls:1.12%
cases:5.32%
controls:3.72%
—
—
—
—
—
5
11
92
967
5
35
89
906
SMOKING - SMOKE2: yes - SMOKE3: current - SMOKE5: current
SMOKING-1-1-1 [2002330115]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:2.42%
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
0
24
99
966
0
6
99
984
—
—
—
—
—
Carcinoembryonic Ag [Mass/volume] in Serum or Plasma
2039-6 [3003785]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
0
6
94
935
ANTIHYPERTENSIVE_DRUG - yes
ANTIHYPERTENSIVE_DRUG-1 [2002330215]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
0
5
94
936
combinations of corticosteroids
D07AB30 [21602118]
1.2e-01
1.1e+00
—
—
—
1.1e+00
1.4e-02
cases:10.10%
controls:9.09%
cases:5.05%
controls:1.82%
—
—
—
—
—
—
cases:6.19%
controls:2.15%
cases:9.57%
controls:9.46%
10
90
89
900
5
18
94
972
—
—
—
6
21
91
957
9
89
85
852
Tissue Pathology biopsy report
66121-5 [40768804]
9.5e-01
—
—
—
—
—
6.9e-01
cases:6.06%
controls:2.42%
—
—
—
—
—
—
—
—
—
—
cases:6.38%
controls:3.29%
6
24
93
966
—
—
—
—
—
6
31
88
910
Pregnancy associated plasma protein A [Multiple of the median] adjusted in Serum or Plasma
76348-2 [46235831]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
99
984
—
—
—
—
—
—
Sneezing/nasal congestion
R07 [2002000888]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
0
5
94
936
Risk factor NOS
A23 [2002000158]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
99
985
—
—
—
—
—
—
Glaucoma suspect
H40.0 [45567051]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
0
6
94
935
cyproterone and estrogen
G03HB01 [21602617]
7.2e-01
—
—
—
—
—
—
cases:6.06%
controls:3.03%
—
—
—
—
—
—
—
—
—
—
—
—
6
30
93
960
—
—
—
—
—
—
Ultrasound screening of fetal nuchal translucency
MA2JE [2001306837]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.17%
0
9
99
981
—
—
—
—
—
0
11
94
930
loperamide oxide; oral
A07DA05 [21600648]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
0
9
94
932
Spinalanesthesia
WX320 [2001310799]
—
—
—
—
—
—
1.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.38%
controls:1.81%
—
—
—
—
—
—
6
17
88
924
glycerol
A06AX01 [21600597]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
0
6
94
935
Dimethyl fumarate, interferon beta, glatiramer acetate and teriflunomid (Multiple sclerosis)
303 [2001600260]
1.0e+50
—
—
—
—
1.0e+50
1.0e+50
cases:9.09%
controls:0.00%
—
—
—
—
—
—
—
—
cases:12.37%
controls:0.00%
cases:9.57%
controls:0.00%
9
0
90
990
—
—
—
—
12
0
85
978
9
0
85
941
Albumin [Mass/volume] in Urine
1754-1 [3012516]
—
—
—
—
—
1.4e+00
4.0e-01
—
—
—
—
—
—
—
—
—
—
cases:5.15%
controls:1.33%
cases:5.32%
controls:3.61%
—
—
—
—
—
5
13
92
965
5
34
89
907
Blepharitis
H01.0 [45533180]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
99
984
—
—
—
—
—
—
Disease/condition unspecnature/site
A99 [2002000232]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
99
985
—
—
—
—
—
—
Diabetes mellitus arising in pregnancy
O24.4 [45543922]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
—
0
8
99
982
—
—
—
—
—
tamsulosin; oral
G04CA02 [21602669]
—
—
—
—
—
—
1.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.32%
controls:0.85%
—
—
—
—
—
—
5
8
89
933
chloramphenicol
G01AA05 [21602367]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.06%
—
—
—
—
—
—
0
10
94
931
Troponin T.cardiac [Mass/volume] in Serum or Plasma
6598-7 [3019800]
—
—
—
—
—
—
1.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.57%
controls:3.29%
—
—
—
—
—
—
9
31
85
910
Phlebitis and thrombophlebitis of superficial vessels of lower extremities
I80.0 [45576919]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
0
5
94
936
Other seropositive rheumatoid arthritis
M05.8 [45538634]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
99
985
—
—
—
—
—
—
combinations of corticosteroids
D07XB30 [21602188]
1.2e-01
1.1e+00
—
—
—
1.1e+00
1.4e-02
cases:10.10%
controls:9.09%
cases:5.05%
controls:1.82%
—
—
—
—
—
—
cases:6.19%
controls:2.15%
cases:9.57%
controls:9.46%
10
90
89
900
5
18
94
972
—
—
—
6
21
91
957
9
89
85
852
Psoriasis vulgaris
L40.0 [45543370]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
99
985
—
—
—
—
—
—
Maternal care due to uterine scar from previous surgery
O34.2 [45572805]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.21%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
99
978
—
—
—
—
—
—
ambroxol; oral
R05CB06 [21603385]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
—
0
7
97
971
—
clindamycin; oral, parenteral
J01FF01 [21602985]
1.8e-01
—
—
—
—
-1.0e+50
—
cases:5.05%
controls:4.24%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
5
42
94
948
—
—
—
—
0
9
97
969
—
chlorhexidine
S02AA09 [21605155]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.06%
—
—
—
—
—
—
0
10
94
931
Trochanteric bursitis
M70.6 [45606304]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
—
0
5
99
985
—
—
—
—
—
Rotator cuff syndrome
M75.1 [45596678]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
0
5
97
973
—
brompheniramine, combinations
R06AB51 [21603466]
5.9e-01
-1.0e+50
—
—
—
—
—
cases:6.06%
controls:3.43%
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
6
34
93
956
0
5
99
985
—
—
—
—
—
salbutamol; oral, parenteral
R03CC02 [21603312]
1.1e+00
—
—
—
—
—
—
cases:7.07%
controls:2.53%
—
—
—
—
—
—
—
—
—
—
—
—
7
25
92
965
—
—
—
—
—
—
Sodium and Potassium panel [Moles/volume] - Serum or Plasma
34548-8 [3045783]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
—
0
6
99
984
—
—
—
—
—
Respiratory infection other
R83 [2002000951]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
—
0
7
97
971
—
Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection
21416-3 [3003510]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
—
0
6
99
984
—
—
—
—
—
Hepatitis C virus Ab [Presence] in Serum
16128-1 [3017143]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.11%
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
0
11
99
979
0
6
99
984
—
—
—
—
—
desogestrel
G03AC09 [21602505]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.11%
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
0
11
99
979
0
5
99
985
—
—
—
—
—
ciclesonide; inhalant
R03BA08 [21603291]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
0
6
94
935
sulfasalazine; oral, rectal
A07EC01 [21600663]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
0
6
94
935
Otitis externa, unspecified
H60.9 [45605727]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.96%
—
—
—
—
—
—
0
9
94
932
terbutaline; inhalant
R03AC03 [21603257]
8.0e-01
—
—
—
—
—
—
cases:5.05%
controls:2.32%
—
—
—
—
—
—
—
—
—
—
—
—
5
23
94
967
—
—
—
—
—
—
Removal of sutures
SPAT1153 [2001700254]
—
—
—
—
—
—
1.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.45%
controls:2.87%
—
—
—
—
—
—
7
27
87
914
General Practice
1 [38004446]
1.1e+00
1.2e+00
—
—
—
—
7.6e-01
cases:13.13%
controls:4.75%
cases:6.06%
controls:1.82%
—
—
—
—
—
—
—
—
cases:13.83%
controls:7.01%
13
47
86
943
6
18
93
972
—
—
—
—
13
66
81
875
Lumbar epidural anesthesia
WX306 [2001310796]
-1.0e+50
—
—
—
—
—
1.4e+00
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
cases:5.32%
controls:1.38%
0
6
99
984
—
—
—
—
—
5
13
89
928
nimesulide; oral
M01AX17 [21604007]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
—
0
6
99
984
—
—
—
—
—
Restricted oral and dental health check by dental hygienist or dental assistant
SAB01 [2001310279]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
99
982
—
—
—
—
—
—
moxifloxacin; oral, parenteral
J01MA14 [21603021]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.06%
0
5
99
985
—
—
—
—
—
0
10
94
931
Necrosis of pulp
K04.1 [45572186]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
cases:0.00%
controls:1.59%
0
6
99
984
—
—
—
—
0
5
97
973
0
15
94
926
chlorhexidine
D09AA12 [21602275]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.06%
—
—
—
—
—
—
0
10
94
931
valsartan and diuretics
C09DA03 [21601836]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.61%
cases:0.00%
controls:0.51%
—
—
—
—
—
—
cases:0.00%
controls:0.61%
cases:0.00%
controls:0.85%
0
6
99
984
0
5
99
985
—
—
—
0
6
97
972
0
8
94
933
Supervision of normal pregnancy
Z34 [45566419]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
0
7
94
934
Psychosocial counselling and guidance
SPAT1307 [2001700408]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
99
981
—
—
—
—
—
—
piroxicam; oral, parenteral, rectal
M01AC01 [21603961]
2.4e-01
—
—
—
—
-1.0e+50
7.1e-01
cases:6.06%
controls:4.85%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.33%
cases:8.51%
controls:4.36%
6
48
93
942
—
—
—
—
0
13
97
965
8
41
86
900
roxithromycin; oral
J01FA06 [21602974]
8.1e-01
—
—
—
—
9.6e-01
—
cases:12.12%
controls:5.76%
—
—
—
—
—
—
—
—
cases:5.15%
controls:2.04%
—
—
12
57
87
933
—
—
—
—
5
20
92
958
—
long-acting sulfonamides - combinations
J01ED20 [21602959]
9.5e-01
—
—
—
—
—
—
cases:6.06%
controls:2.42%
—
—
—
—
—
—
—
—
—
—
—
—
6
24
93
966
—
—
—
—
—
—
Human papilloma virus DNA [Presence] in Specimen by NAA with probe detection
49891-5 [3029511]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
99
985
—
—
—
—
—
—
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
4.2e-02
-1.4e-02
1.6e+00
—
1.0e+00
6.0e-01
4.4e-01
cases:11.11%
controls:10.71%
cases:8.08%
controls:8.18%
cases:5.05%
controls:1.01%
—
—
cases:5.05%
controls:1.92%
cases:11.34%
controls:6.54%
cases:24.47%
controls:17.32%
11
106
88
884
8
81
91
909
5
10
94
980
—
5
19
94
971
11
64
86
914
23
163
71
778
chorionic gonadotrophin; parenteral
G03GA01 [21602599]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
0
7
94
934
Tear of meniscus, current
S83.2 [45555441]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
0
5
94
936
Observation for suspected disease or condition, unspecified
Z03.9 [45552062]
—
—
—
—
—
—
9.0e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.32%
controls:2.23%
—
—
—
—
—
—
5
21
89
920
Rhinopharyngoscopy
UDH02 [2001301680]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
0
8
94
933
Endocrinology
46 [38004485]
—
-1.0e+50
-1.0e+50
—
-1.0e+50
—
1.6e-01
—
—
cases:0.00%
controls:2.32%
cases:0.00%
controls:0.91%
—
—
cases:0.00%
controls:1.01%
—
—
cases:5.32%
controls:4.57%
—
0
23
99
967
0
9
99
981
—
0
10
99
980
—
5
43
89
898
Type 1 diabetes mellitus, Without complications
E10.9 [45581351]
—
-1.0e+50
-1.0e+50
—
-1.0e+50
-1.0e+50
—
—
—
cases:0.00%
controls:3.33%
cases:0.00%
controls:0.91%
—
—
cases:0.00%
controls:1.21%
cases:0.00%
controls:3.89%
—
—
—
0
33
99
957
0
9
99
981
—
0
12
99
978
0
38
97
940
—
Dorsalgia
M54 [45553203]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
99
983
—
—
—
—
—
—
betamethasone
A07EA04 [21600656]
5.7e-01
—
—
—
—
-1.0e+50
5.5e-01
cases:7.07%
controls:4.14%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.64%
cases:9.57%
controls:5.74%
7
41
92
949
—
—
—
—
0
16
97
962
9
54
85
887
Hemoglobin A1c/Hemoglobin.total in Blood
4548-4 [3004410]
3.9e-01
8.8e-02
—
—
—
5.5e-01
-9.4e-02
cases:10.10%
controls:7.07%
cases:5.05%
controls:4.65%
—
—
—
—
—
—
cases:8.25%
controls:4.91%
cases:13.83%
controls:14.98%
10
70
89
920
5
46
94
944
—
—
—
8
48
89
930
13
141
81
800
Cholesterol non HDL [Moles/volume] in Serum or Plasma
70204-3 [42868678]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.59%
—
—
—
—
—
—
0
15
94
926
Feeling anxious/nervous/tense
P01 [2002000798]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
—
0
6
99
984
—
—
—
—
—
Acute suppurative otitis media
H66.0 [45572040]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.85%
0
8
99
982
—
—
—
—
—
0
8
94
933
Cholesterol [Moles/volume] in Serum or Plasma
14647-2 [3019900]
5.0e-01
4.2e-01
—
—
—
4.3e-01
8.2e-02
cases:13.13%
controls:8.38%
cases:7.07%
controls:4.75%
—
—
—
—
—
—
cases:8.25%
controls:5.52%
cases:18.09%
controls:16.90%
13
83
86
907
7
47
92
943
—
—
—
8
54
89
924
17
159
77
782
metoclopramide; oral, parenteral, rectal
A03FA01 [21600484]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
0
8
97
970
—
venlafaxine; oral
N06AX16 [21604745]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.57%
controls:2.44%
—
—
—
—
—
—
9
23
85
918
Periodontal treatment, very brief
SDA01 [2001310326]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
cases:0.00%
controls:0.51%
cases:0.00%
controls:4.46%
—
0
10
99
980
—
—
—
0
5
97
973
0
42
94
899
lymecycline; oral, parenteral
J01AA04 [21602802]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
—
0
5
99
985
—
—
—
—
—
Hypertrophy of breast
N62 [45577538]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
0
6
94
935
Recurrent depressive disorder, currently in remission
F33.4 [45533100]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
99
983
—
—
—
—
—
—
erdosteine; oral
R05CB15 [21603394]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
99
985
—
—
—
—
—
—
insulins and analogues for injection, intermediate-acting - combinations; parenteral
A10AC30 [21600727]
-1.0e+50
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:2.42%
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
0
24
99
966
—
—
—
0
6
99
984
—
—
Surveillance of (intrauterine) contraceptive device
Z30.5 [45547300]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.06%
—
—
—
—
—
—
0
10
94
931
Chronic asthma and similar chronic obstructive pulmonary diseases
203 [2001600201]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
0
8
94
933
hydrocortisone buteprate
D07AB11 [21602115]
2.0e-01
—
—
—
—
—
—
cases:7.07%
controls:5.86%
—
—
—
—
—
—
—
—
—
—
—
—
7
58
92
932
—
—
—
—
—
—
chloramphenicol
S03AA08 [21605197]
—
—
—
—
—
—
1.3e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.38%
controls:5.63%
—
—
—
—
—
—
6
53
88
888
Urology
34 [38004474]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.38%
controls:1.70%
—
—
—
—
—
—
6
16
88
925
Follow-up examination after surgery for other conditions
Z09.0 [45576131]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
0
9
99
981
—
—
—
—
—
0
5
94
936
Stomatognathic treatment, simple
SHA01 [2001310405]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
0
5
97
973
—

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
37
74
7.24
19.37
6.6
2.4
9.25
10.28
g/l
0.97
37
69
25
13
24.89
17.96
1.2
1.1
—
—
—
0
0
88
470
6.99
13.53
20.9
6.1
0.57
0.53
e9/l
0.73
82
409
88
472
6.94
13.41
20.8
6.1
0.04
0.04
e9/l
0.20
82
407
67
292
4.70
13.27
18.0
5.6
—
—
—
0
0
88
478
6.77
13.03
20.9
6.2
1.68
1.89
e9/l
1.33
83
427
82
426
5.54
12.67
20.6
6.0
57.07
56.61
%
0.13
82
405
48
171
4.38
12.29
4.9
2.5
5.74
12.57
e6/l
0.78
40
153
88
493
6.39
12.13
21.0
6.3
0.20
0.18
e9/l
0.69
83
437
42
138
4.45
11.92
5.3
2.5
567.25
503.22
mosm/kgh2o
1.07
36
116
15
7
24.72
11.05
2.7
1.7
50.15
35.24
%
—
15
7
30
84
4.63
10.31
1.7
1.5
—
—
—
0
0
74
391
4.17
10.27
23.0
9.2
0.00
0.00
e9/l
0.03
68
310
52
224
3.67
9.69
8.1
2.7
0.12
0.27
e6/l
0.73
44
153
52
226
3.63
9.52
7.7
2.6
—
—
estimate
—
0
0
18
22
9.66
9.04
1.2
1.3
—
—
—
0
0
56
262
3.49
9.02
8.1
2.9
22.59
23.38
e6/l
0.02
47
189
52
235
3.45
8.81
4.2
2.3
—
—
—
0
0
84
525
4.25
8.26
23.4
10.3
3.67
3.95
e9/l
0.65
79
458
75
459
3.33
7.11
7.3
3.1
0.00
0.00
estimate
-0.00
24
97
35
139
3.30
7.07
2.1
1.5
—
—
—
0
0
58
309
3.01
7.01
10.1
3.5
8.91
56.04
e6/l
2.18
49
204
42
188
3.08
6.91
2.0
1.7
—
—
—
0
0
75
465
3.25
6.84
7.2
3.2
0.00
0.00
estimate
-0.00
23
97
43
197
3.03
6.77
6.1
3.3
—
—
—
0
0
22
67
3.90
6.59
6.2
4.9
0.17
0.40
%
—
6
15
75
473
3.15
6.48
7.3
3.3
0.00
0.00
estimate
-0.00
23
87
22
69
3.78
6.31
6.6
4.7
0.33
0.44
%
—
6
18
31
123
3.17
6.19
7.8
2.6
4.53
2.50
e6/l
0.48
19
53
21
65
3.80
6.13
6.8
4.9
0.00
0.00
%
—
5
14
22
72
3.61
5.92
7.5
4.8
0.17
0.13
%
—
6
16
15
29
5.87
5.66
1.9
1.5
—
—
—
0
0
85
600
3.38
5.58
10.3
4.0
—
—
—
0
0
9
8
12.17
5.40
1.1
1.4
—
—
—
0
0
61
373
2.56
5.11
5.5
2.9
6.41
6.15
ph
0.97
34
198
43
228
2.52
4.82
2.9
1.4
1.73
2.21
g/l
1.51
35
147
46
253
2.48
4.76
8.0
3.3
0.00
0.00
estimate
-0.00
24
92
21
77
3.17
4.69
1.8
1.4
—
16.93
—
0
7
8
8
10.71
4.60
1.0
1.5
2.06
2.20
mmol/l
—
8
8
47
269
2.37
4.38
15.2
6.4
—
—
—
0
0
54
340
2.24
3.90
10.7
10.9
1.12
1.14
inr
0.10
46
282
8
12
7.12
3.75
1.5
1.1
—
—
—
0
0
53
342
2.13
3.49
7.4
3.0
0.00
0.00
estimate
-0.00
20
78
42
257
2.07
3.10
5.7
2.6
0.00
0.01
estimate
0.49
21
75
38
224
2.10
3.10
2.4
1.9
—
—
—
0
0
24
121
2.28
2.85
5.0
3.1
4.30
4.30
e9/l
0.00
24
104
13
50
2.83
2.65
2.8
1.7
0.00
0.00
estimate
—
8
14
18
83
2.42
2.59
2.7
1.8
0.25
0.00
estimate
—
8
18
12
45
2.89
2.55
5.2
1.7
—
—
—
0
0
37
239
1.86
2.22
12.3
4.7
—
—
—
0
0
9
30
3.19
2.21
1.2
1.5
—
—
—
0
0
8
26
3.25
2.06
1.8
2.8
13.60
10.36
mg/l
—
8
26
33
211
1.83
2.02
2.2
1.9
0.68
1.22
mg/l
0.95
22
168
5
11
4.71
1.96
2.4
1.2
—
—
—
0
0
31
197
1.82
1.93
6.6
3.3
1.02
1.02
kg/l
0.48
23
119
30
192
1.79
1.82
18.2
3.8
—
—
—
0
0
20
117
1.88
1.59
3.5
2.0
—
—
—
0
0
53
409
1.61
1.56
10.7
6.4
1.22
1.22
mmol/l
0.22
47
362
18
103
1.91
1.53
13.8
7.3
104.00
104.41
mmol/l
0.12
18
103
7
28
2.61
1.48
12.3
5.9
37.10
36.92
°c
—
7
28
37
268
1.59
1.39
2.7
2.4
52.38
69.71
u/l
0.55
37
251
36
260
1.59
1.36
1.4
1.3
0.80
1.57
u/ml
—
10
79
5
18
2.86
1.30
1.0
1.3
—
—
—
0
0
36
264
1.56
1.27
1.7
1.6
—
—
—
0
0
8
37
2.26
1.24
1.3
1.1
—
—
—
0
0
21
135
1.70
1.24
1.8
2.3
116.13
84.36
ug/g
0.27
16
110
16
95
1.81
1.22
2.3
1.9
264.87
373.36
nmol/l
1.49
16
89
24
161
1.64
1.21
1.8
1.5
560.00
642.35
titre
—
9
34
23
153
1.65
1.20
3.0
2.6
2.46
2.45
mmol/l
0.12
23
136
7
30
2.43
1.15
1.7
1.3
—
—
—
0
0
22
148
1.62
1.10
4.2
3.4
16.00
459.52
ng/l
1.12
13
98
13
75
1.84
1.08
8.8
2.9
—
—
—
0
0
12
69
1.84
1.01
24.5
8.3
—
—
—
0
0
11
62
1.87
0.98
4.7
8.9
119.27
122.39
g/l
0.20
11
62
39
305
1.45
0.98
2.7
3.3
46.17
27.31
ng/l
0.28
25
171
7
37
1.96
0.96
27.0
4.2
25.06
24.72
mmol/l
—
7
37
19
128
1.59
0.94
2.2
1.6
—
—
—
0
0
8
42
1.98
0.91
11.4
2.2
0.51
0.59
%
—
8
42
8
43
1.93
0.90
11.4
2.3
1.86
1.37
%
—
8
43
12
72
1.75
0.89
5.1
8.6
7.43
7.43
ph
—
7
38
8
45
1.84
0.86
3.9
11.7
96.01
93.89
%
—
8
45
0
25
0.00
0.80
0.0
1.0
—
0.70
—
0
12
33
259
1.40
0.80
10.2
3.5
7.42
7.40
ph
1.63
24
181
0
26
0.00
0.79
0.0
1.0
—
2.88
—
0
16
18
127
1.51
0.74
1.3
1.2
—
—
—
0
0
18
128
1.49
0.72
1.4
1.2
—
—
—
0
0
94
894
1.59
0.66
28.8
13.6
139.70
139.94
mmol/l
0.48
94
880
50
430
1.32
0.66
3.9
2.6
—
—
estimate
—
0
0
10
63
1.65
0.64
1.5
1.2
—
—
—
0
0
80
854
0.72
0.64
4.3
3.9
1.28
1.25
mmol/l
0.18
73
801
34
278
1.33
0.63
5.2
2.1
—
—
—
0
0
0
23
0.00
0.59
0.0
2.0
—
7.43
—
0
23
95
905
1.64
0.59
29.3
13.1
15.19
20.09
mg/l
0.93
83
730
6
37
1.66
0.56
2.0
1.6
—
—
—
0
0
16
117
1.44
0.56
1.8
1.3
—
—
—
0
0
6
38
1.61
0.55
7.2
7.2
15.67
16.12
%
—
6
38
6
38
1.61
0.55
3.7
2.0
0.19
0.23
g/l
—
6
38
36
415
0.80
0.47
2.8
2.8
—
—
—
0
0
80
751
1.29
0.45
5.9
4.7
14.71
14.52
pmol/l
0.32
74
711
0
15
0.00
0.41
0.0
1.8
—
5.12
—
0
15
0
15
0.00
0.41
0.0
1.8
—
9.46
—
0
15
84
878
0.77
0.40
4.4
4.4
5.67
5.74
mmol/l
0.24
79
826
25
208
1.27
0.40
1.3
1.3
3.92
6.15
u/ml
—
9
82
9
68
1.35
0.39
1.1
1.1
—
—
—
0
0
98
951
1.63
0.37
33.9
15.8
64.90
70.26
umol/l
2.73
98
939
6
43
1.42
0.35
3.5
2.7
21.17
20.66
s
—
6
38
86
893
0.78
0.35
4.6
4.7
1.52
1.52
mmol/l
0.04
80
849
6
87
0.67
0.34
7.0
4.1
6.83
5.36
ug/l
—
6
67
91
877
1.32
0.33
7.1
5.5
1.71
1.77
mu/l
0.22
86
826
7
100
0.68
0.32
1.0
1.5
—
—
—
0
0
88
907
0.80
0.27
5.0
5.2
2.82
2.83
mmol/l
0.05
82
866
5
72
0.68
0.27
1.6
1.9
—
—
—
0
0
5
70
0.70
0.27
1.4
1.2
80.20
105.51
u/ml
—
5
62
9
75
1.22
0.26
3.7
1.3
—
—
—
0
0
5
38
1.33
0.23
1.4
1.3
—
—
—
0
0
25
221
1.17
0.23
1.3
1.3
14.08
17.79
iu/ml
—
6
73
44
408
1.14
0.21
3.6
2.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.9
—
—
—
0
0
0
10
0.00
0.21
0.0
1.3
—
90.90
—
0
10
0
10
0.00
0.21
0.0
1.5
—
1.48
—
0
10
0
12
0.00
0.21
0.0
3.7
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
11.5
—
0.67
—
0
13
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
14
0.00
0.20
0.0
2.0
—
—
—
0
0
39
362
1.12
0.18
3.0
2.0
98.68
97.74
pmol/l
0.03
24
190
8
70
1.15
0.17
1.4
1.2
—
—
—
0
0
22
239
0.90
0.12
7.5
3.3
84.47
30.59
mg/l
0.31
12
141
5
43
1.17
0.10
1.2
1.1
0.80
0.98
g/l
—
5
43
5
44
1.14
0.10
2.8
4.3
7.43
7.42
ph
—
5
36
23
247
0.91
0.10
3.1
3.4
—
—
—
0
0
15
165
0.89
0.09
1.4
1.5
—
—
—
0
0
12
107
1.14
0.09
3.3
4.7
1.04
1.58
ug/l
0.67
12
87
12
108
1.13
0.07
1.7
1.5
—
—
—
0
0
94
946
0.93
0.07
20.0
10.9
—
—
—
0
0
23
244
0.93
0.07
7.7
3.8
14.11
5.37
mg/mmol
—
10
141
25
263
0.93
0.06
8.6
3.1
7.45
7.30
mmol/l
0.05
19
220
40
411
0.96
0.04
2.1
1.8
1.30
1.38
mmol/l
0.24
34
359
11
105
1.05
0.00
1.5
1.3
—
—
—
0
0
10
99
1.01
0.00
1.4
1.1
—
—
—
0
0
5
49
1.02
0.00
9.2
7.1
24.80
25.66
mmol/l
—
5
49
0
8
0.00
-0.00
0.0
3.7
—
1.21
—
0
8
0
6
0.00
-0.00
0.0
39.5
—
136.83
—
0
6
0
9
0.00
-0.00
0.0
3.3
—
32.44
—
0
9
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
3.7
—
3.91
—
0
8
0
7
0.00
-0.00
0.0
3.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
10.04
—
0
5
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.6
—
118.50
—
0
8
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
53.80
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
138.38
—
0
7
0
8
0.00
-0.00
0.0
3.7
—
106.87
—
0
8
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
4.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
10.9
—
1106.38
—
0
8
0
8
0.00
-0.00
0.0
2.1
—
67.38
—
0
8
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0

Mortality – FinRegistry

↥

This endpoint is excluded (different definition than used in FinnGen).

Relationships between endpoints

↥

Index endpoint: G6_NMO – Neuromyelitis optica

GWS hits: -

This endpoint is excluded (different definition than used in FinnGen).